Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:GILD
Raised
Post IPO Valuation

General Information

Websitegilead.com
Bloggileadyeffett.wor...
Twitter@GileadSciences
CategoryBioTech
Phone(650) 574-3000
Employees
Founded1987

Offices

Foster City, USA
333 Lakeside Drive
Foster City, CA, 94404
USA

People

President and COO,Chief Financial Officer, Director of Project Management and Project Team Leader
Board Member
Chairman and CEO, President and Chief Executive Officer
Executive Vice President, Research and Development and Chief Scientific Officer
Executive Vice President, Corporate and Medical Affairs, General Counsel, Associate General Counsel, Attorney
Executive Vice President, Commercial Operations
Senior Vice President and Chief Financial Officer
Senior Vice President, Human Resources
Show All People

Acquisitions

Total$720M
Calistoga Pharmaceuticals, 2/2011 $375M
Arresto BioSciences, 12/2010 $225M
CGI Pharmaceuticals, 6/2010 $120M

Tags

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases.

Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

There portfolio of 13 marketed products includes a number of category firsts and market leaders, including Atripla® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. The company’s first product for HIV infection, Viread® (tenofovir disoproxil fumarate), has also more recently been approved for the treatment of chronic hepatitis B. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus, is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million (investors.gilead.com) [edit]
  2. Gilead Sciences To Acquire Arresto BioSciences For $225M Cash (fis.dowjones.com) [edit]
  3. Gilead to buy CGI Pharm for $120M (fiercebiotech.com) [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy